InMed Pharmaceuticals, Inc. (IMLFF)

Our latest clients all have the potential to grow significantly in the near and long-term future

InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Fri Mar 03, 2017 1:07 pm

InMed Pharmaceuticals, Inc. (IMLFF) is a preclinical-stage biopharmaceutical company specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids. Utilizing its proprietary bioinformatics assessment tool, InMed aims to identify bioactive compounds found within the cannabis plant that have the potential to offer optimized therapeutic benefit while demonstrating limited adverse effects. This assessment tool, in combination with the company's cannabinoid biosynthesis technology and drug development pipeline, serves as InMed's fundamental value driver.

Bioinformatics is a proprietary, computer-based program designed to assist in the identification of novel cannabinoids using comprehensive algorithms to integrate data from numerous bioinformatics databases, as well as a database on the structure of currently approved pharmaceutical products and an extensive database on over 90 individual cannabinoid drugs found in cannabis. This extensive collection of data is derived from both public and propriety-based sources. Leveraging this tool, the company aims to create associations between approved pharmaceuticals and cannabinoids with similar structures in order to identify active cannabinoids that have the potential to treat specific diseases. Per InMed's website, this type of bioinformatics assessment represents "significant promise for future drug discovery, as it integrates many data sets and builds holistic models to approach a specific disease."

After discovering these promising active cannabinoids, InMed moves to test and confirm their activity in biological systems through in vitro and in vivo experimentation. It is at this stage of development that the company's proprietary biosynthesis process of cannabinoid manufacturing will be most promising. InMed is currently developing a robust, high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. By modifying the agriculture-based formula for harvesting cannabinoids, InMed aims to combine the inherent safety and known efficacy of the natural drug structure with the convenience, control and quality of 21st Century laboratory-based manufacturing processes.

The company's pipeline currently includes two drug candidates in preclinical development, including INM-750 for the treatment of epidermolysis bullosa (EB) and INM-085 for the treatment of glaucoma. Referred to by the Dystrophic Epidermolysis Bullosa Research Association of America as "The Worst Disease You've Never Heard Of," EB is a rare genetic connective tissue disorder that affects roughly one out of every 20,000 births in the United States. The condition currently has no approved treatment or cure. Through the development of INM-750, InMed is attempting to address this significant unmet medical need. The drug candidate replaces missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

INM-085, InMed's second development candidate, is formulated to reduce the elevated intra-ocular pressure that is often associated with glaucoma. Additionally, the cannabinoids utilized in INM-085 are expected to provide neuroprotection for the retinal ganglion cells and other optic nerve tissues following topical administration. Although it is still in preclinical development, INM-085 targets a sizable market. According to the Glaucoma Research Foundation, glaucoma is a leading cause of blindness with no approved cure. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and more than 120,000 have been blinded by the disease.

InMed is focused on progressing toward validation of its drug candidate selection, using data to secure its patents and developing key disruptive technologies. In 2016, the company was successful in completing financings of $1.9 million. In January 2017, InMed completed a non-brokered private placement of common shares generating aggregate gross proceeds of C$1.5 million, strongly positioning the company to attract the new investment required to fund its aggressive growth strategies in 2017.

The company's management team has well over a century of combined experience in the biopharmaceutical space. Company CEO Eric Adams has more than 25 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance. During his time as CEO of enGene Inc., he led the gene therapy startup to a position at the head of the industry.

Joining Adams on the InMed management team are Chief Scientific Officer Dr. Sazzan Hossain; Senior Vice President, Clinical and Regulatory Affairs Alexandra D.J. Mancini; SVP, Corporate Strategy & Investor Relations Chris Bogart; and Chief Financial Officer Jeff Charpentier, as well as Chief Medical Officer Dr. Ado Muhammed, MD, DPM, MFPM.

Muhammed, in particular, has an extensive history in the pharmaceutical industry, having previously served as an executive of GW Pharmaceuticals, a global leader in the development of cannabinoid-based medicines. During his time as Associate Medical Director of that company, Muhammed played an instrumental role in the development and FDA approval of one of the first cannabis drugs. This GW Pharmaceuticals development program coincided with a sharp rise in share price from less than $9 in 2013 to more than $129 today, with the company's current market value totaling more than $2.9 billion. Investment Considerations Extensive portfolio of assets in dermatology, ocular disease and additional indications and cannabinoid biosynthesis Positioned to achieve value-driving, near-term corporate milestones with limited investment Led by a management team of experienced professionals capable of building value in biopharmaceuticals Additional Resources Newsroom Presentation Website
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 302
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Wed Mar 15, 2017 5:54 pm

Biotech Innovations Drive Cannabinoid-Based Pharmaceutical Market Growth

As the medical marijuana market continues to grow, so does the number of biotech companies expanding their research into the development of innovative cannabinoid-based pharmaceuticals and delivery systems. It is estimated that the U.S. consumer market for cannabinoid pharmaceuticals will increase exponentially in upcoming years, exceeding $50 billion by 2029, according to Statista. This doesn’t appear to be a lofty forecast, given the prominence this market segment has gained by the sustained efforts and innovations of leading biotech companies such as InMed Pharmaceuticals, Inc. (IMLFF) (InMed Profile), GW Pharmaceuticals plc (GWPH), Zynerba Pharmaceuticals, Inc. (ZYNE), AXIM® Biotechnologies, Inc. (AXIM) and OWC Pharmaceutical Research Corp. (OWCP). From multiple sclerosis symptoms to gastrointestinal problems and rare skin conditions, cannabinoids are increasingly demonstrating potential for a variety of medical conditions. The biotech companies developing and commercializing these new therapies are on a path to market stardom.

Topical delivery, targeting to treat diseases on a local (rather than systemic) basis, is a preferred approach for various cannabinoid therapies, especially those targeting skin conditions. Canada-based InMed Pharmaceuticals, Inc. (IMLFF) (InMed Profile), flagship product, INM-750, is a cannabinoid-based topical therapy for a rare skin condition called Epidermolysis Bullosa (EB). INM-750 is the first treatment ever developed specifically for this disease. Although, as of now, there is no cure for EB, INM-750 has the potential to accelerate wound healing and skin regeneration; alleviate several symptoms such as inflammation, itching and pain; and modulate keratin levels in the skin, with potentially regenerative and restorative effects. With a potential global market of $1 billion per year, the treatment is being developed for topical application so as to maximize efficacy while minimizing side effects. InMed’s second product candidate, INM-085, is targeting glaucoma and is also being developed for topical (eye drop) application. With an estimated 2.7 million patients in the U.S. and a global market exceeding $5 billion, INM-085 will be the first glaucoma treatment designed to be a multi-mechanism, multi-target of action therapy based on cannabinoids.

In addition to its innovative drug delivery systems, what sets InMed apart further is its groundbreaking, proprietary biosynthesis process for the manufacture of all 90+ known cannabinoids that occur naturally in the marijuana plant. This cost-effective, innovative approach has already proven successful at laboratory scale, and it is likely to make InMed a game-changer in the booming cannabinoid pharmaceutical market. Most biotech companies in the field, including giants such as GW Pharmaceuticals (GWPH), focus on traditional cannabinoid extraction methods that require tons of marijuana plants and tens of millions of dollars in expenses. This costly process is also resource intensive, with various factors that can impact quality control, just to get the two most common cannabinoids: tetrahydrocannabinol (THC) and cannabidiol (CBD). The extraction of less common cannabinoids is even more expensive, making such traditional processing methods highly unfeasible.

But InMed’s biosynthesis process, much like Eli Lilly’s current method for making human insulin, can change all of that. The company’s high-yield/low-cost approach will allow the industry to tap into the potential of cannabinoids present in marijuana plants by creating them in a laboratory setting in a safe and scalable manner. With its top-tier management and board, which includes Chief Scientific Officer and global leader in cannabinoid science Dr. Sazzad Hossain and Chief Medical Officer Ado Muhammed – a former senior member of GW Pharmaceuticals and a proven leader in the development of cannabinoid-based therapies, InMed has the right expertise, the right team and the right science to cause a major shift in the market and turn it into a billion-dollar business.

Another company that focuses on transdermal cannabinoid-based therapies with very encouraging results is Israel’s OWC Pharmaceutical Research Corp. (OWCP). The company manufactures products for various conditions, including PTSD, multiple myeloma, migraines and psoriasis, and it is focused on the development and optimization of two proprietary delivery systems: a sublingual tablet and a topical compound. OWC’s research efforts are spearheaded by Chief Science Officer Dr. Yehuda Baruh, former head of the medical cannabis program of the Israeli Ministry of Health for over 10 years. Last month, the company received Institutional Board Review approval to run safety testing on its topical cream for the treatment of psoriasis and related conditions, making it the first topical delivery mechanism and proprietary cannabinoid-based psoriasis formulation to be included in the NIH Registry.

Yet another innovative delivery method for cannabinoid-based therapies comes from AXIM® Biotechnologies, Inc. (AXIM). With a market cap of $490 million, AXIM® is a leading cannabinoid research and development company that focuses on creating pharmaceutical, cosmetic and nutraceutical products. Its pharmaceutical products target mostly pain, anxiety and spasticity, as well as other medical conditions that can benefit from cannabinoid-based treatments. Its flagship products both use an innovative delivery method, being manufactured in the form of chewing gum, including: CanChew® – a CBD-based controlled release product for the treatment of irritable bowel syndrome (IBS), and MedChew Rx – a CBD/THC combination currently undergoing clinical trials for the treatment of multiple sclerosis-associated pain and spasticity. The company recently announced the launch of a phase 2 clinical trial for CanChew Plus®, which enrolls 40 trial patients suffering from IBS.

Another successful cannabis biotech company, Zynerba Pharmaceuticals, Inc. (ZYNE), has taken the process one step further, focusing on the development of novel synthetic cannabinoid treatments designed for transdermal delivery. With a market cap of more than $260 million and a stock price of over $20 per share, Zynerba is developing two proprietary therapies: a synthetic tetrahydrocannabinol pro-drug transdermal patch for peripheral neuropathic pain and fibromyalgia, and a transdermal synthetic cannabinoid gel for osteoarthritis, fragile X syndrome and refractory epilepsy. Earlier this year, the company launched an underwritten public offering of 2.8 million shares at $18 per share, with expected proceeds of over $50 million to continue funding the clinical development of its proprietary therapies.

As mentioned above, GW Pharmaceuticals plc (GWPH) is a leading industry player and a clear example of a medical marijuana firm whose stock has been skyrocketing as a result of successfully isolating different cannabinoids from marijuana plants and turning them into efficient medical therapies. The UK-based biopharmaceutical company has discovered an oromucosal spray for multiple sclerosis spasticity, which is already being successfully marketed in dozens of countries. Furthermore, it has isolated another cannabinoid to be used for the treatment of epilepsy, which is currently in the final clinical trial states before approval, and the company is also developing other product candidates for a wide range of medical conditions such as tuberous sclerosis complex, Dravet syndrome, infantile spasms, Lennox-Gastaut syndrome, glioma and schizophrenia. The company’s success in developing effective and innovative cannabinoid-based therapies over the last few years has earned it a market cap of more than $3 billion and a share price of over $120.

For more information on InMed Pharmaceuticals, Inc. (IMLFF) please visit: https://www.inmedpharma.com/insights/2017
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 302
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Thu Mar 16, 2017 4:13 pm

InMed Pharmaceuticals (IMLFF) Lead Product Candidate Targeting Rare, Incurable Skin Disease

With a prevalence of 20 per million newborns in the United States, and an estimated 500,000 patients worldwide, epidermolysis bullosa is a group of rare inherited skin diseases that range in severity from mild to lethal and have no currently approved or known cure or treatment. The condition was brought to the public attention in the early 2000s, and, since then, efforts to find a cure have not born fruit, with most research and development focusing instead on addressing the symptoms, such as reducing blistering and swelling and preventing wounds and pain. However, a new product currently in development by Vancouver-based biopharmaceutical company InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) may change that, having the potential to basically reverse the disease.

The condition causes extreme skin sensitivity that often results in painful blisters on the dermis or mucosal membranes, as a result of minor trauma such as heat or scratching or friction. Usually showing up in infancy or early childhood, the disease has various symptoms such as the appearance of large blisters on the skin, mostly on the feet and hands; loss of fingernails or toenails; blistering in the respiratory system, blistering on the scalp and hair loss; difficulty swallowing; dental problems and more. In its more severe forms, epidermolysis bullosa can cause complications such as sepsis, malnutrition and anemia, dehydration, eye disorders and even skin cancer. In some severe cases where blistering is widespread, frequent infections and sores affect the patients’ ability to breathe and eat and ultimately result in their death.

This orphan disease has no known treatment, and it is therefore a significant unmet medical need that InMed Pharmaceuticals, focusing on the research and development of innovative cannabinoid-based therapies, is working to fill. According to InMed, cannabinoid compounds have recognized analgesic, anti-inflammatory, and wound healing properties, which make them excellent candidates to alleviate some of the symptoms associated with this condition.

The company’s lead product candidate, INM-750, is the first therapy developed specifically for epidermolysis bullosa, being designed both to alleviate symptoms and target dermis imbalances that may ultimately provide a cure. INM-750 targets cannabinoid receptors in the skin to help accelerate wound healing, reduce pain and itching, reduce inflammation, and more. By upregulating specific keratins in the skin, INM-750 may also help reestablish the epidermal junction and essentially reverse the condition for patients with epidermolysis bullosa simplex (EBS) – the most common form of the disease.

Earlier this month, InMed filed an international Patent Cooperation Treaty application for intellectual and commercial protection of INM-750 and a cannabinoid-based therapy for EBS. This marks a significant milestone for the company, serving as validation for its efforts to develop new therapies based on cannabinoids and its unique approach to drug development. The company is using a proprietary bioinformatics assessment tool to identify what bioactive cannabis compounds can offer the optimal therapeutic benefits, with limited side effects and a proprietary biosynthesis technology to manufacture and test these compounds in biological systems via in vitro and in vivo experimentation. These proprietary systems and its drug development pipeline are the company’s core assets.

For more information, visit the company’s website at www.InMedPharma.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 302
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Thu Apr 06, 2017 4:27 pm

InMed Pharmaceuticals, Inc. (IMLFF) Adds to Its Drug Development Pipeline

A pre-clinical stage biopharmaceutical company, InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) has revealed two additions to its drug development pipeline. An expedited drug development timeline is now in place for INM-750 for epidermolysis bullosa (EB), with a potential market of about $1 billion. The disease is characterized by fragile skin in children. The company has also announced the development of INM-085 for glaucoma, which represents a potential global market of over $5 billion.

Resulting in a defect in the connective tissue between the dermis and epidermis, most often caused by a lack of keratins, EB currently has no medication-based treatments. Multiple cannabinoids are the active ingredients of INM-750, which is now under development as a topical drug. These were selected to manage keratin levels in people with EB, in which fragile skin can blister and tear easily with the slightest friction or trauma. The cannabinoids were also chosen to address inflammation, itching, wound healing, pain, and skin regeneration.

One of the leading causes of blindness, glaucoma is associated with high fluid pressure in the eye, which can damage the optic nerve. The first glaucoma treatment of its kind, INM-085 will be a multi-target, multi-mechanism therapy. It will contain multiple cannabinoids that can reduce elevated intra-ocular pressure and protect retinal ganglion cells and optic nerve tissues. The drug will be designed to be applied directly to the eye as a topical formulation.

The new drugs in development are in addition to the company’s other initiatives, including a number of cannabinoid-based drugs. Dr. Ado Muhammed, MD, DPM, MFPM, chief medical officer of IMLFF, is a leader in developing cannabinoid therapies. Prior to joining InMed, he served as executive on board at GW Pharmaceuticals (NASDAQ: GWPH), where he was involved in the development and regulatory approval of one of the first prescription cannabis-based drugs on the market. Muhammed has had strategic roles in the research and development, clinical development, and commercialization of specialty drugs.

InMed’s core assets also include a computer-based drug/disease target screening tool and a proprietary cannabinoid manufacturing system. The bioinformatics tool has helped InMed identify novel cannabinoids thanks to algorithms that have allowed the integration of data from various bioinformatics databases. It also uses a database of approved pharmaceutical products and one consisting of over 90 cannabinoid drugs. The company has used the tool to associate approved pharmaceuticals with cannabinoids that have similar structures in order to identify which ones will act on specific genes and proteins.

A biosynthesis system is in development, which is based on similar processes that use bacteria and yeast in industrial applications. It will allow InMed to manufacture naturally occurring cannabinoids in the laboratory at high yields. An alternative to chemical manufacturing methods, it could address production, quality control, purification, and structural integrity. The system is expected to be a revolution in the rapidly emerging cannabinoid pharmaceutical sector.

For more information, visit the company’s website at www.InMedPharma.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 302
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Mon Apr 10, 2017 3:38 pm

InMed Pharmaceuticals, Inc. (IMLFF) Offers More than Just a Non-THC Cannabinoid Drug Pipeline

Now that 28 states have passed comprehensive medical marijuana laws, conditions have never looked better for expanding research and development (R&D) into the therapeutic benefits of cannabinoids, which is exactly what InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF) is doing. Its efforts have already borne results: the company has two novel drug candidates in its pipeline. But there’s more to InMed than meets the eye; the Vancouver, Canada-based company has developed a proprietary process to manufacture cannabinoids based on biosynthesis. In addition, it has constructed an algorithm to identify the cannabinoids most likely to have beneficial therapeutic effect. With this triad of core assets, InMed looks poised to join the ranks of Big Pharma.

Of the 480 or so substances found in the cannabis sativa plant, about 60 are unique to the plant and are called cannabinoids. Perhaps the best known of these is delta-9-tetrahydrocannabinol (THC), which is responsible for the ‘high’ derived from marijuana, but cannabinol (CBN) and cannabinodiol (CBDL) will also get you stoned. Most other cannabinoids are not psychoactive and cannabidiol (CBD), the one which occurs the most in the plant (about 40 percent of cannabis resin), actually mitigates the psychoactive effects of THC.

CBD is also known to dispel anxiety, which, according to the Anxiety and Depression Association of America (http://nnw.fm/hI96V), is the most common mental illness in the U.S., afflicting 40 million Americans. Cannabinoid R&D has the potential not only to ease their suffering but the burden of those who suffer from a variety of other ailments.

At InMed, R&D has led to the development of a proprietary process to manufacture cannabinoids. Traditionally, cannabinoid compounds have been isolated by processing and purifying cannabis resin from actual plants. Alternatively, synthetic cannabinoids are created in the lab in a costly, time-consuming process that, in the end, may not produce a substance quite like nature’s. The InMed approach is to apply cannabinoid DNA to E-coli bacteria. The E-coli DNA is then removed leaving just the cannabinoid DNA, which can then replicate, in a process known as biosynthesis.

Although novel as a means of developing cannabinoids, biosynthesis is widely employed in the pharmaceutical industry. For example, the insulin used by millions of diabetics worldwide on a daily basis is manufactured through biosynthesis.

InMed has also created a bioinformatics program that assists in the identification of novel cannabinoids to treat diseases based on the current non-cannabinoid drugs being used. The program uses comprehensive algorithms to integrate data from numerous bioinformatics databases, including a database on the structure of currently approved pharmaceutical products, and an extensive database on over 90 individual cannabinoid drugs found in cannabis.

Using its own proprietary analytics program and manufacturing methodology, InMed has advanced two drug candidates along its pipeline. The first, INM-750, is for the treatment of a rare genetic connective tissue disorder, called epidermolysis bullosa (EB), that affects roughly one out of every 20,000 births in the United States. The condition, which currently has no approved treatment or cure, has been called “The Worst Disease You’ve Never Heard Of” by the Dystrophic Epidermolysis Bullosa Research Association of America. INM-750 works by replacing missing keratins in the skin with specially selected cannabinoids in an effort to modulate the painful manifestations of EB.

Also in pre-clinical trials is INM-085 for the treatment of glaucoma, a leading cause of blindness, according to the Glaucoma Research Foundation. The drug reduces the elevated intra-ocular pressure that is often associated with glaucoma. It is targeting a large market. The National Institutes of Health estimates that more than 3 million Americans currently have glaucoma, and that the disease has blinded more than 120,000.

InMed continues to expand its cannabinoid R&D. This has already produced huge success for GW Pharmaceuticals (market cap: $3 billion) after its Sativex, derived from cannabis, was approved for the treatment of multiple sclerosis (MS).

For more information, visit the company’s website at www.InMedPharma.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 302
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Tue Apr 11, 2017 4:15 pm

The Value Drivers of InMed Pharmaceuticals, Inc. (IMLFF)

The cannabis plant is comprised of, among other things, phytochemicals that have evolved over time to become very biologically active. Most of the current research and development (R&D) surrounding cannabis revolves around understanding these biologically-active ingredients, especially cannabinoids. To date, over 90 cannabinoids have been isolated from cannabis, each affecting the body’s cannabinoid receptors and responsible for distinctive pharmacological effects. The cannabinoids that bind more selectively to certain receptors have become more desirable for medical usage because of the advantage offered. Examples of phytochemicals that have been developed into pharmaceutical drugs include the bronchodilator (asthma), salicin (aspirin) and a number of cardiovascular agents.

InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) is a Canadian drug discovery and development company with a unique focus on this area of cannabinoid science and the curative capabilities of cannabinoids. Since the 1980s, InMed has been developing a robust pipeline of therapies and products by leveraging its primary value drivers: its leadership team and its research and development into the extensive pharmacology of cannabinoids; its proprietary drug discovery platform; its proprietary cannabinoid manufacturing system; and its inventive drug delivery systems.

InMed benefits from the leadership of tested experts like Dr. Ado Muhammed, the company’s Chief Medical Officer. A proven leader in the field of cannabinoid therapies, Muhammed previously served as Associate Medical Director at GW Pharmaceuticals, a $3 billion cannabis biotechnology company. There, he played a strategic role in the delivery of core clinical research and key decision-making regarding R&D and product commercialization. Moreover, he was instrumental in leading that company through the development and regulatory approval of one of the first cannabis drugs in existence. InMed prides itself on being the only cannabis biotech company with a former GW Pharmaceuticals executive on board. This is a significant occurrence, as GW Pharmaceuticals is viewed as “the cannabis industry leader,” as well as a long-term biotech investment with a promising future. Since 2013, GW Pharmaceuticals’ shares have shot up from less than $9 to over $121 as of March 30, 2017, bringing it to a market value of approximately $2.9 billion.

Bioinformatics assessment is another of InMed’s core value drivers. As a general approach, this type of assessment opens up the world for future drug discovery, as it combines scores of data sets and builds holistic models to approach a specific disease. As part of its operations, InMed has created a computer-based program that assists in the discovery of novel cannabinoids using: (a) far-reaching algorithms to integrate data from various bioinformatics databases, (b) a database on the structure of currently-approved pharmaceutical products, and (c) a broad database containing the 90-plus individual cannabinoid drugs that have been found in cannabis. The company is now using this bioinformatics assessment tool to classify bioactive compounds within the cannabis plant that have the potential to have physiological impacts on specific diseases and to, ultimately, identify new drug candidates that heighten the therapeutic benefits of cannabis while restricting its adverse effects.

Biosynthesis — a process used in industrial applications, including the use of bacteria- or yeast-based systems for the production of pharmaceuticals — is also one of InMed’s primary value drivers. InMed is currently building up a high-yield biosynthesis process for manufacturing all 90+ naturally-occurring cannabinoids. This process integrates the inbuilt safety and known effectiveness of natural drug structures with the convenience, control and quality of a laboratory-based manufacturing process. InMed’s proprietary approach to the production of pharmaceutical grade, bio-identical cannabinoids is a disruptive technology in the current and rapidly-emerging cannabinoid pharmaceutical sector.

Along with its proprietary in silico drug/disease bioinformatics assessment tool and its cannabinoid biosynthesis technology, InMed’s drug development pipeline is also a core asset. The company is leveraging a conservative clinical budget and accelerated drug development timelines to target unmet medical conditions using its disease-specific formulations. Presently, the company has two drug candidates in its pipeline:

INM-750 is under pre-clinical development for the treatment of epidermolysis bullosa, an orphan pediatric disease that is typified by extremely fragile skin. Epidermolysis bullosa has no current approved therapies and represents an estimated $1 billion market.
INM-085 is under pre-clinical development for the treatment of glaucoma, a severe eye disease with a global market of approximately $5.6 billion.
InMed Pharmaceuticals is also seeking and developing novel drug candidates for the treatment of conditions relating to dermatology, pain and inflammation, metabolic and respiratory diseases, and the ocular region and central nervous system.

For more information, visit the company’s website at www.InMedPharma.com
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 302
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ

Re: InMed Pharmaceuticals, Inc. (IMLFF)

Postby QualityStocks » Wed May 10, 2017 4:21 pm

NetworkNewsBreaks – InMed Pharmaceuticals (IMLFF) Announces Filing of Provisional Patent for INM-085

Pre-clinical stage biopharmaceutical company InMed Pharmaceuticals, Inc. (OTCQB: IMLFF) (CSE: IN) this morning announced the filing of a provisional patent application in the United States for INM-085 as a cannabinoid-based topical therapy for glaucoma. The company notes that this move marks an important step toward providing intellectual and commercial protection for INM-085. If approved, INM-085 could address an expansive global market that’s currently valued in excess of $5 billion. Per this morning’s update, glaucoma is currently the second-leading cause of blindness, driven by risk factors such as increased pressure in the eye, a family history of the condition, migraines, high blood pressure and obesity. With INM-085, InMed is seeking to reduce intraocular pressure associated with glaucoma through a single daily eye drop administered immediately prior to the patient’s bedtime. The company also intends to initiate discussions with potential partners regarding its proprietary delivery system for ophthalmic drugs, which it anticipates could play a key role in reducing the high rates of non-adherence that are often present with currently-approved glaucoma therapies.
The QualityStocks Daily Newsletter http://Newsletter.QualityStocks.net

The QualityStocks Daily Blogs http://Blog.QualityStocks.net

Please read FULL Compensation Disclosures and other disclaimers at http://www.qualitystocks.net/disclaimer.php
QualityStocks
Site Admin
 
Posts: 302
Joined: Mon May 21, 2007 7:58 pm
Location: Scottsdale, AZ


Return to QualityStocks Featured Companies

Who is online

Users browsing this forum: No registered users and 1 guest

cron